The Long COVID Treatment Trial

NCT07128082 on ClinicalTrials.gov · last registry update 2025-12-23

An unusually large phase 2: 1,000 participants, more than double the 110 typical for the stage. Due to report December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS). Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Scripps Translational Science Institute
Sponsor type: Other
Enrollment: 1,000
Started: 2025-10-30
Primary completion: 2026-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS)

Conditions studied

Long COVID

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.